Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094284 | 0.87 | MAPT (0.44) | MAPTMEN1MAPK1KMT2APPIA | |
| SCHEMBL5103879 | 0.86 | BTK (0.35) | MEN1MAPK1KMT2AL3MBTL1GHSR | |
| SCHEMBL5104037 | 0.84 | KMT2A (0.33) | MEN1MAPK1KMT2AGHSRBTK | |
| SCHEMBL1350921 | 0.83 | MAPT (0.47) | MAPTMEN1MAPK1KMT2APPIA | |
| SCHEMBL1820679 | 0.83 | MAPT (0.39) | MAPTMEN1MAPK1KMT2APPIA | |
| SCHEMBL978565 | 0.82 | MAPT (0.50) | MAPTMEN1MAPK1KMT2APPIA | |
| SCHEMBL1353132 | 0.82 | MAPT (0.50) | MAPTMEN1MAPK1KMT2APPIA | |
| SCHEMBL22362839 | 0.81 | MEN1 (0.35) | MEN1MAPK1KMT2AGHSRCTSL | |
| SCHEMBL28715425 | 0.81 | MEN1 (0.35) | MEN1MAPK1KMT2AGHSRDGAT1 | |
| SCHEMBL5197158 | 0.78 | MAPT (0.39) | MAPTMEN1MAPK1KMT2APPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439263-B2 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-21 | — | — | US | disclosed |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | DPP4, DPP3, NR4A1 | MAPT 4424/4885MEN1 3591/4885MAPK1 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.